A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Apr 2025 Planned End Date changed from 1 Mar 2025 to 1 Sep 2025.
04 Apr 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Sep 2025.
26 Feb 2025 According to a Sarepta Therapeutics media release, this trial is one of the clinical-stage programs covered under the collaboration agreement with Arrowhead Pharmaceuticals, under which Sarepta has obtained exclusive global rights from Arrowhead to four clinical-stage and three preclinical-stage programs.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com